Nu-Med Plus, Inc. engages in the design, development, and marketing of technologies utilizing nitric oxide in the medical device field. The company is headquartered in Salt Lake City, Utah and currently employs 2 full-time employees. The company went IPO on 2013-08-02. The company focuses on the creation of a nitric oxide (NO) generating formulation, a hospital bedside NO delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. The Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery offers a range of concentrations and flow rates of NO.
最新の財務諸表(Form-10K)によると、Nu-Med Plus Incの総資産は$0で、純損失は$0です。
NUMDの主要な財務比率は何ですか?
Nu-Med Plus Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Nu-Med Plus Incの収益はセグメントまたは地域別にどのように分けられていますか?
Nu-Med Plus Inc の最大収益セグメントは Total Commercial Services で、最新の利益発表における収益は 241,925,000 です。地域別に見ると、United States が Nu-Med Plus Inc の主要市場であり、収益は 437,984,000 です。